The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 /PRNewswire/ ...

LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong ...

If drug developers are allowed to skip this step, it will mean that, in the near future, the first living body a new drug is ...

Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs of efficacy- Initial data expected in mid-2026 ...

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 ...

Procedural flexibility incorporated into many cancer clinical trials during the COVID-19 pandemic had no long-term negative ...

A first-of-its-kind solution for women’s arousal in a proprietary topical formulation demonstrated to work where women need ...

On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose ...

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the treatment – called trontinemab – could be the ...

Nations that lead in clinical trials get earlier access to breakthrough therapies, shape global regulatory norms, and ...

As early as 2005, Gritz and colleagues drew attention to clinical trialists missing the potential impact of tobacco use on cancer treatment outcomes, as smoking status was rarely recorded in cancer ...